Can 10x Genomics, Inc. cover its short-term obligations?

Its current ratio is 5.90 — current assets exceed current liabilities.

Where does 10x Genomics, Inc.'s balance sheet data come from?

Every line is extracted from 10x Genomics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

10x Genomics, Inc. TXG Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$473.97M+37.8%	$344.07M-4.2%	$359.28M+58.0%	$227.35M-61.9%
Short-term investments	$49.44M+0.2%	$49.34M+67.7%	$29.41M-86.0%	$210.24M—
Accounts receivable, net	$193.32M-45.4%	$353.87M-7.9%	$384.3M+12.9%	$340.49M+21.3%
Inventories	$261.98M-24.9%	$348.62M+8.7%	$320.62M+8.8%	$294.6M+52.1%
Raw materials	$16.02M-58.8%	$38.93M+12.9%	$34.48M0.0%	$34.5M+8.0%
Work in process	$17.14M-37.6%	$27.44M+24.9%	$21.98M-10.9%	$24.65M+75.4%
Finished goods	$23.18M+38.5%	$16.74M-3.0%	$17.25M-23.3%	$22.48M+61.0%
Prepaid expenses and other current assets	$87.33M+12.0%	$77.97M-0.7%	$78.51M+15.7%	$67.83M+21.8%
Total current assets	$684.45M+17.1%	$584.39M-2.0%	$596.02M-6.1%	$635.04M-15.1%
Property and equipment, net	$226.71M-10.3%	$252.65M-9.6%	$279.57M-3.4%	$289.33M+70.7%
Accumulated depreciation	$153.46M+24.8%	$122.97M+18.8%	$103.49M+50.4%	$68.83M—
Operating lease right-of-use assets	5.9%-5,728,999,994%	5,729,000,000%-807,100,000%	6,536,100,000%-452,100,000%	6,988,200,000%+896,400,000%
Goodwill	$4.51M0.0%	$4.51M0.0%	$4.51M0.0%	$4.51M0.0%
Intangible assets, net	$62.33M+298%	$15.67M-5.7%	$16.62M-27.3%	$22.86M-10.0%
Other non-current assets	$2.91M-29.5%	$4.13M+34.8%	$3.06M+28.0%	$2.39M-27.9%
Total assets	$1.04B+13.4%	$918.64M-4.8%	$965.14M-6.2%	$1.03B+1.0%
Accounts payable	$56.81M-29.5%	$80.58M-7.4%	$87.02M-2.1%	$88.88M+34.4%
Accrued expenses	$42.5M+26.4%	$33.62M+11.7%	$30.11M-7.9%	$32.68M+3.3%
Deferred revenue	$23.9M+15.7%	$20.66M+57.1%	$13.15M+67.2%	$7.87M+47.3%
Operating lease liabilities, current	$10.99M+18.3%	$9.29M-19.4%	$11.52M+27.5%	$9.04M+76.1%
Contract liabilities	$10.5M-16.1%	$12.51M+42.0%	$8.81M+178%	$3.17M-58.9%
Income taxes payable	$7.22M+46.3%	$4.94M-2.2%	$5.05M+23.8%	$4.08M-11.7%
Total current liabilities	$153.45M+30.5%	$117.63M-7.5%	$127.16M-2.9%	$130.96M+18.7%
Operating lease liabilities, non-current	$73.38M+0.1%	$73.33M-12.5%	$83.85M-2.7%	$86.14M+12.1%
Operating Lease Liabilities (Total)	$84.36M+2.1%	$82.61M-13.4%	$95.37M+0.2%	$95.18M+16.1%
Other non-current liabilities	$6.47M+28.7%	$5.03M+17.6%	$4.28M+43.6%	$2.98M-63.9%
Total liabilities	$245.04M+17.5%	$208.5M-7.0%	$224.1M+0.4%	$223.24M+10.9%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%
Additional paid-in capital	$2.31B+5.9%	$2.18B+7.5%	$2.03B+10.1%	$1.84B+9.4%
Retained earnings	-$1.51B-3.0%	-$1.47B-14.2%	-$1.28B-24.8%	-$1.03B-19.2%
Accumulated other comprehensive income (loss)	$225K+146%	-$493K-14.9%	-$429K+90.1%	-$4.34M-19,805%
Total stockholders' equity	$796.33M+12.1%	$710.13M-4.2%	$741.04M-8.0%	$805.74M-1.4%
Total liabilities and stockholders' equity	$1.04B+13.4%	$918.64M-4.8%	$965.14M-6.2%	$1.03B+1.0%
Available For Sale Securities Debt Securities Current	$49.44M+0.2%	$49.34M+67.7%	$29.41M-86.0%	$210.24M—
Finished goods	$23.18M+38.5%	$16.74M-3.0%	$17.25M-23.3%	$22.48M+61.0%
Materials and supplies	$16.02M-58.8%	$38.93M+12.9%	$34.48M0.0%	$34.5M+8.0%
Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)	$35.48M+5,755%	$606K—	——	——
Other Receivables	$35.48M+5,755%	$606K—	——	——
Deferred Tax Assets and Other Non-Current Assets	$2.91M-29.5%	$4.13M+34.8%	$3.06M+28.0%	$2.39M-27.9%
Finite Lived Intangible Assets - Gross	$77.42M+200%	$25.78M—	——	——
Net Investment in Lease	$60.45M+5.5%	$57.29M-12.3%	$65.36M-6.5%	$69.88M+14.7%
Intangible assets — net	$62.33M+298%	$15.67M—	——	——
Other intangible assets—net	$62.33M+298%	$15.67M-5.7%	$16.62M-27.3%	$22.86M-10.0%
Operating lease right-of-use assets	$60.45M+5.5%	$57.29M-12.3%	$65.36M-6.5%	$69.88M+14.7%
Other non-current assets	$2.91M-29.5%	$4.13M+34.8%	$3.06M+28.0%	$2.39M-27.9%
Property, plant and equipment at cost	$380.18M+1.2%	$375.62M-1.9%	$383.06M+7.0%	$358.16M—
Operating Lease Right-of-Use Assets in Other Assets	$60.45M+5.5%	$57.29M-12.3%	$65.36M-6.5%	$69.88M+14.7%
Software and Technology Licenses, Net	$2.91M-29.5%	$4.13M+34.8%	$3.06M+28.0%	$2.39M-27.9%
Accrued Manufacturing Costs	$42.5M+26.4%	$33.62M+11.7%	$30.11M-7.9%	$32.68M+3.3%
Accrued Progress Collections and Price Adjustments	$10.5M-16.1%	$12.51M+42.0%	$8.81M+178%	$3.17M—
Accrued Royalties (Current)	$4.97M-29.4%	$7.04M+29.1%	$5.46M+15.9%	$4.71M+6.6%
Accrued Expenses And Other Liabilities Current	$39.97M-2.9%	$41.17M-27.3%	$56.65M-5.2%	$59.78M—
Compensation and benefits	$42.5M+26.4%	$33.62M+11.7%	$30.11M-7.9%	$32.68M+3.3%
Other accrued liabilities	$11M+20.1%	$9.16M+108%	$4.41M-34.2%	$6.71M+27.1%
Current portion of accrued product warranty	$6.83M-20.7%	$8.62M+6.1%	$8.12M+168%	$3.02M+204%
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Professional Service Fees Payable	$2.91M-45.2%	$5.32M-19.2%	$6.58M+27.0%	$5.18M-39.7%
Standard Product Warranty Accrual	$6.83M-20.7%	$8.62M+6.1%	$8.12M+168%	$3.02M+204%
Contract Liabilities, Non-Current	$10.5M-16.1%	$12.51M+42.0%	$8.81M+178%	$3.17M—
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——
Deferred revenue, net of current portion	$10.5M-16.1%	$12.51M+42.0%	$8.81M+178%	$3.17M—
Total debt	$84.36M+2.1%	$82.61M-13.4%	$95.37M+0.2%	$95.18M+16.1%
Additional paid-in capital	$2.31B+5.9%	$2.18B+7.5%	$2.03B+10.1%	$1.84B+9.4%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Share-Based Payment - Nonvested Awards (Number)	7.8M+20.5%	6.5M+21.7%	5.3M-8.6%	5.8M+350%
Share-Based Payment Award Options Outstanding - Number	3.6M-22.5%	4.6M-22.7%	5.9M-25.3%	8M-3.0%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	$19.68-44.6%	$35.55-26.3%	$48.26-7.6%	$52.21-63.1%
Unrealized Gains on Investments	$12K-33.3%	$18K—	$0-100%	$4K—
Unrealized Losses on Investments (Before Tax)	$0—	$0-100%	$188K-95.4%	$4.12M—
Weighted Average Exercise Price of Outstanding Options	$48.55+7.0%	$45.37+7.6%	$42.17+13.7%	$37.10+26.7%
Cumulative Cost Basis	$380.18M+1.2%	$375.62M-1.9%	$383.06M+7.0%	$358.16M—
Accrued bonuses	$29.51M+35.0%	$21.86M+19.7%	$18.25M+6.9%	$17.08M+3.2%
Accrued commissions	$5.34M-10.2%	$5.94M-7.4%	$6.41M+24.6%	$5.14M+50.5%
Accrued Legal And Related Expenses Current	$1.5M-75.4%	$6.1M+58.9%	$3.84M—	——
Accrued Payroll And Related Costs	$4.96M+67.1%	$2.97M+31.3%	$2.26M+10.2%	$2.05M-48.4%
Professional service fees	$2.91M-45.2%	$5.32M-19.2%	$6.58M+27.0%	$5.18M-39.7%
Licensing Arrangements	$4.97M-29.4%	$7.04M+29.1%	$5.46M+15.9%	$4.71M+6.6%
Contingent liabilities	$23.36M—	——	——	——
Asset Acquisition Contingent Consideration Liability Noncurrent	$1.24M—	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$0—	$0-100%	$188K-95.4%	$4.12M—
Gross Unrealized Gains	$12K-33.3%	$18K—	$0-100%	$4K—
Contract with Customer, Liability	$34.4M+3.7%	$33.17M+50.8%	$22M+100%	$11M+42.9%
Customer refunds and deposits payable	$5.54M—	——	——	——
Debt Securities, Available For Sale, Amortized Cost Including Money Market Funds	$490.54M+32.1%	$371.33M-1.8%	$378.14M+0.2%	$377.54M—
Total available-for-sale securities, fair value	$490.55M+32.1%	$371.35M-1.7%	$377.95M+1.2%	$373.42M—
Finite-Lived Intangible Assets, Accumulated Amortization	$15.09M+49.3%	$10.11M—	——	——
Gross Carrying Amount	$77.42M+200%	$25.78M—	——	——
Lessee Operating Lease Liability Payments Due	——	——	——	——
Thereafter	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.06+1.7%	$0.06-1.7%	$0.06+7.3%	$0.06+1.9%
Other Employee Related Liabilities Current	$2.7M-5.4%	$2.85M-10.4%	$3.18M+8.5%	$2.93M+675%
Standard and Extended Product Warranty Accrual	$6.83M-20.7%	$8.62M+6.1%	$8.12M+168%	$3.02M+204%
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value	$19.68-44.6%	$35.55-26.3%	$48.26-7.6%	$52.21-63.1%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$3.56M-22.5%	$4.59M-22.7%	$5.95M-25.3%	$7.96M-3.0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$48.55+7.0%	$45.37+7.6%	$42.17+13.7%	$37.1+26.7%
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number	$7.83M+20.5%	$6.49M+21.7%	$5.33M-8.6%	$5.84M+350%
Remainder of Fiscal Year 2024	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can 10x Genomics, Inc. cover its short-term obligations?: Its current ratio is 5.90 — current assets exceed current liabilities.
Where does 10x Genomics, Inc.'s balance sheet data come from?: Every line is extracted from 10x Genomics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.